Advent Therapeutics Awarded $3 Million NIH Grant For Novel Neonatal Lung Therapy

July 20, 2023

Advent Therapeutics, Inc., a biotechnology company pioneering an optimized retinol palmitate (vitamin A) drug product as a breakthrough non-invasive inhaled neonatal lung therapy, has been awarded a $3 million National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Phase IIB grant. This grant allows the Company to position its novel aerosolized vitamin A formulation […]

Read More

Cagent Vascular Announces Initial RECOIL Study Results: Serranator Demonstrates 49% Less Recoil Than POBA In BTK Arteries

July 19, 2023

Cagent Vascular, the exclusive developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its Below-the-Knee (BTK) RECOIL study. This Core Lab-Adjudicated Recoil analysis, the first of its kind, evaluated vessel recoil in lesions treated with Serranator® verses Plain Old Balloon Angioplasty (POBA). The study results demonstrated that lesions treated using […]

Read More

VESTECK Continues To Help Patients Around The World

June 1, 2023

VESTECK, Inc. is excited to announce the successful completion of 7 Endovascular Aortic Repair (EVAR) clinical cases with the “SUTURE-TIGHT”™ device. Professor Dainis Krievins and Dr. Bao Bui, performed the 2 most recent EVAR procedures in Riga, Latvia, suturing EVAR grafts to the aorta with the “SUTURE-TIGHT”™ catheter. This brings VESTECK, Inc. to a total of 7 clinical cases […]

Read More

First All-Metal Patient-Specific Instrument In Ankle Arthroplasty

April 23, 2023

Axiom PSR is made of titanium alloy, which means it will have better durability compared to implants made from ceramic or polyethene. Restor3d has received approval from the Food and Drug Administration (FDA) for the first all-metal patient-specific instrument (PSI) in ankle arthroplasty. This product, named Axiom PSR, will be added to Kinos Medical’s total […]

Read More

Across Q1 And Q2, Ben Franklin Tech Partners Is Investing Nearly $3M Into 12 Philly-Area Startups

February 7, 2023

Plus, the state-backed investment firm is raising a $25 million fund, similar to the Go Philly Fund from 2019 in partnership with Newtown-headquartered EPAM. It’s a busy start to the year for Ben Franklin Technology Partners‘ (BFTP) Southeastern Pennsylvania branch. The state-backed firm recently announced it’s slated to make investments in seven local startup companies. The […]

Read More

Ben Franklin Technology Partners Invests $2M In 7 Philadelphia-Area Startups, Plans New $25M Fund

February 6, 2023

Ben Franklin Technology Partners of Southeastern Pennsylvania is investing $2 million in Philadelphia-area tech and health care startups before setting its sights on a new late-stage fund with a goal of raising at least $25 million — a welcome commitment for local startups as venture capital funding dries up. The investments were made in two […]

Read More

‘A Little Company With A Big Vision’: Temple Spinout Advancing New Way To Treat Autoimmune Disorders

January 12, 2023

A Temple University spinout working on a new way to treat autoimmune disorders has been approved to begin human testing of a potential treatment for an inflammatory liver disease. SFA Therapeutics of Jenkintown received Food and Drug Administration clearance to begin a Phase 1 clinical trial of the company’s new drug candidate SFA-001N, which it […]

Read More

Startups To Watch

January 6, 2023

13 Philadelphia-area startups ready to reach new heights in 2023 Despite a somewhat tumultuous 2022, Greater Philadelphia’s startup ecosystem has continued to flourish. This past year, startups and their founders adapted after a record-setting 2021 that saw the region post its largest annual funding total to date. The first half of 2022 was almost equally […]

Read More

Neuraptive Therapeutics Raises $19.5M, Expands Management Team

November 2, 2022

A Philadelphia biotechnology company working on therapeutics and medical products for patients impacted by peripheral nerve injuries has raised $19.5 million from private investors. The equity financing was disclosed in documents Center City-based Neuraptive Therapeutics filed with the Securities and Exchange Commission. Company officials were not available to comment on the stock sale. Neuraptive is […]

Read More

A Bold Effort To Cure HIV—Using Crispr

October 11, 2022

An experiment tests whether the gene-editing technology can stop the virus from replicating, which would ultimately wipe out the infection. IN JULY, AN HIV-positive man became the first volunteer in a clinical trial aimed at using Crispr gene editing to snip the AIDS-causing virus out of his cells. For an hour, he was hooked up to […]

Read More